Frontlight ResearchEarly access
Active, not recruitingNo phase
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Key facts
- Who runs it
- Regeneron Pharmaceuticals
- Where
- Atlanta, Aurora, Boston, Camp Hill, Chapel Hill, Charleston, Charlottesville, Chicago, Durham, Farmington, Flowood, Fort Sam Houston, Houston, Kansas City, La Jolla, Lake Success, Layton, Libertyville, Little Rock, Littleton, Los Angeles, Mentor, Milwaukee, Nashville, New Haven, New York, Oakland, Ocean City, Orange City, Orlando, Owensboro, Palo Alto, Philadelphia, Phoenix, Rochester, San Francisco, Seattle, Skokie, Southlake, St Louis, Summerville, Sun City, Tacoma, Wichita, and Winston-Salem, United StatesSee the 54 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 368 people enrolled
- Started
- 22 Nov 2024
- Expected to end
- 22 May 2030
- Type of study
- Observational
- Treatments tested
- dupilumab
- Record updated
- 12 August 2026
Who can take part
- Age
- 1 year and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Initiating treatment with DUPIXENT® for EoE according to the USPI
- Participants aged ≥12 years and caregivers or legal guardians of participants aged <12 years must be able to understand and complete registry-related questionnaires
Who cannot take part
- Treatment with DUPIXENT® within the 6 months prior to the screening assessment
- Patients who have a contraindication to DUPIXENT® according to the USPI
- Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator); NOTE: Other protocol defined inclusion/exclusion criteria apply
Where in United States
- Emory Healthcare, Emory ClinicAtlanta, United States
- GI Care for Kids LLCAtlanta, United States
- Childrens Hospital ColoradoAurora, United States
- University of Colorado Anschutz Medical CampusAurora, United States
- Boston Childrens HospitalBoston, United States
- Boston Specialists, Chinatown OfficeBoston, United States
- Massachusetts General HospitalBoston, United States
- Susquehanna Research GroupCamp Hill, United States
- University of North Carolina at Chapel HillChapel Hill, United States
- Medical University of South CarolinaCharleston, United States
- University of VirginiaCharlottesville, United States
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States
- Northwestern University Feinberg School of MedicineChicago, United States
- Duke UniversityDurham, United States
- UConn Health - The Carole and Ray Neag Comprehensive Cancer CenterFarmington, United States
- GI Associates and Endoscopy CenterFlowood, United States
- Brooke Army Medical CenterFort Sam Houston, United States
- Baylor College of MedicineHouston, United States
- Kansas City VA Medical CenterKansas City, United States
- Scripps ClinicLa Jolla, United States
- Steven And Alexandra Cohen Children's Medical Center Of New YorkLake Success, United States
- Tanner ClinicLayton, United States
- Comprehensive Gastrointestinal Health, LLCLibertyville, United States
- Arkansas Childrens HospitalLittle Rock, United States
- Rocky Mountain GastroenterologyLittleton, United States
- University of California Los Angeles (UCLA).Los Angeles, United States
- University of Southern California Keck School of MedicineLos Angeles, United States
- Great Lakes Gastroenterology Research, LLCMentor, United States
- Medical College of WisconsinMilwaukee, United States
- Vanderbilt University Medical CenterNashville, United States
- Yale School of MedicineNew Haven, United States
- Icahn School of Medicine at Mount SinaiNew York, United States
- Weil Cornell Medicine NYPNew York, United States
- University of California San FranciscoOakland, United States
- Allergy Partners of N.J., P.C.Ocean City, United States
- Gastroenterology of Greater OrlandoOrange City, United States
- Orlando HealthOrlando, United States
- Allergy & Asthma Specialists, P.S.C.Owensboro, United States
- Stanford UniversityPalo Alto, United States
- The Children's Hospital Of PhiladelphiaPhiladelphia, United States
- University of PennsylvaniaPhiladelphia, United States
- Phoenix Childrens HospitalPhoenix, United States
- Gastroenterology Group Of Rochester, LLPRochester, United States
- Mayo ClinicRochester, United States
- University of California, San Francisco (UCSF)San Francisco, United States
- Seattle Children's Home Health CompanySeattle, United States
- Endeavor Health, Skokie CampusSkokie, United States
- GI AllianceSouthlake, United States
- Washington University in Saint LouisSt Louis, United States
- Palmetto Gastroenterology Clinical ResearchSummerville, United States
- Arizona Digestive Health/GI AllianceSun City, United States
- Washington Gastroenterology- GIATacoma, United States
- Kansas Gastroenterology, LLCWichita, United States
- Atrium Health / Wake Forest University School of MedicineWinston-Salem, United States
About the trial
What the trial wants to find out
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab).
Read full original descriptionShow less
The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE.
Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward.
Patient questionnaires will measure the following:
* How EoE makes one feel * EoE signs and/or symptoms, eg, how difficult it is to swallow * How EoE affects quality-of-life * How EoE impacts aspects of daily life * How EoE symptoms have changed throughout the study
The group in the trial
- EoE Patients treated with DUPIXENT®
Treatment: dupilumab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care
- Publications
- Record updated
- 12 August 2026